Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Tingley

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Psychophysiology|June 5, 2009
AKAP10 (I646V) functional polymorphism predicts heart rate and heart rate variability in apparently healthy, middle-aged European-AmericansSerina A Neumann, Whittemore G Tingley, Bruce R Conklin, et al.
The American Journal of Cardiology|February 17, 2018
Corrigendum to 'Effects of RG7652, a Monoclonal Antibody Against PCSK9, on Low-Density Lipoprotein Cholesterol (LDL-C), LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or with Established Coronary Heart Disease (From the Phase 2 EQUATOR Study)' The American Journal of Cardiology 119 (2017) 1576-1583Amos Baruch, Sofia Mosesova, John D Davis, et al.
The American Journal of Cardiology|March 28, 2017
Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study)Amos Baruch, Sofia Mosesova, John D Davis, et al.
Clinical Cardiology|March 23, 2017
A phase 1 study to evaluate the safety and LDL cholesterol-lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9Amos Baruch, Diana Luca, Robert S Kahn, et al.
BMC Medical Genomics|March 30, 2011
Development of a blood-based gene expression algorithm for assessment of obstructive coronary artery disease in non-diabetic patientsMichael R Elashoff, James A Wingrove, Philip Beineke, et al.
Cardiovascular Research|November 9, 2025
First-in-human study of TN-201, an AAV9 gene replacement therapy in MYBPC3-associated hypertrophic cardiomyopathy: initial safety, pharmacodynamic, and imaging results from MyPEAK-1Milind Y Desai, Sherif F Nagueh, John R Giudicessi, et al.
Annals of Internal Medicine|October 6, 2010
Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patientsSteven Rosenberg, Michael R Elashoff, Philip Beineke, et al.
Nature Communications|March 4, 2025
AAV9-mediated MYBPC3 gene therapy with optimized expression cassette enhances cardiac function and survival in MYBPC3 cardiomyopathy modelsAmara Greer-Short, Anna Greenwood, Elena C Leon, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Psychophysiology|June 5, 2009
AKAP10 (I646V) functional polymorphism predicts heart rate and heart rate variability in apparently healthy, middle-aged European-AmericansSerina A Neumann, Whittemore G Tingley, Bruce R Conklin, et al.
The American Journal of Cardiology|February 17, 2018
Corrigendum to 'Effects of RG7652, a Monoclonal Antibody Against PCSK9, on Low-Density Lipoprotein Cholesterol (LDL-C), LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or with Established Coronary Heart Disease (From the Phase 2 EQUATOR Study)' The American Journal of Cardiology 119 (2017) 1576-1583Amos Baruch, Sofia Mosesova, John D Davis, et al.
The American Journal of Cardiology|March 28, 2017
Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study)Amos Baruch, Sofia Mosesova, John D Davis, et al.
Clinical Cardiology|March 23, 2017
A phase 1 study to evaluate the safety and LDL cholesterol-lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9Amos Baruch, Diana Luca, Robert S Kahn, et al.
BMC Medical Genomics|March 30, 2011
Development of a blood-based gene expression algorithm for assessment of obstructive coronary artery disease in non-diabetic patientsMichael R Elashoff, James A Wingrove, Philip Beineke, et al.
Cardiovascular Research|November 9, 2025
First-in-human study of TN-201, an AAV9 gene replacement therapy in MYBPC3-associated hypertrophic cardiomyopathy: initial safety, pharmacodynamic, and imaging results from MyPEAK-1Milind Y Desai, Sherif F Nagueh, John R Giudicessi, et al.
Annals of Internal Medicine|October 6, 2010
Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patientsSteven Rosenberg, Michael R Elashoff, Philip Beineke, et al.
Nature Communications|March 4, 2025
AAV9-mediated MYBPC3 gene therapy with optimized expression cassette enhances cardiac function and survival in MYBPC3 cardiomyopathy modelsAmara Greer-Short, Anna Greenwood, Elena C Leon, et al.
Pageof 2